<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00349830</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-13535</org_study_id>
    <secondary_id>77923</secondary_id>
    <secondary_id>IRB-13535</secondary_id>
    <secondary_id>VAR0006</secondary_id>
    <secondary_id>5R01CA18829804</secondary_id>
    <nct_id>NCT00349830</nct_id>
  </id_info>
  <brief_title>Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy</brief_title>
  <official_title>Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the levels of serum proteins and other biomarkers in&#xD;
      cancer patients and in patients suspected of having cancer. We believe that some of these&#xD;
      markers may be useful for confirming the diagnosis or for selecting patients for specific&#xD;
      types of cancer therapies. These markers may also help to predict response to therapy,&#xD;
      relapse after therapy, and survival after therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a blood serum collection study at Stanford University for patients with cancer at a&#xD;
      variety of disease sites. The purpose of this study is to collect and store blood serum from&#xD;
      patients before, during, and after anti-cancer therapy to find new biomarkers that signal&#xD;
      disease or response to anti-cancer therapy. The collection and analysis of these biomarkers&#xD;
      may lead to improved diagnostic and treatment therapies for certain cancers in the future. We&#xD;
      are also interested in collecting blood serum from healthy individuals such as the spouses,&#xD;
      relatives, and friends of cancer patients to obtain healthy controls for comparison&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers for disease</measure>
    <time_frame>Day one</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Carcinomas (Including Squamous Cell and Adenocarcinoma)</condition>
  <condition>Neoplasms</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood draw</intervention_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        cancer patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Age &gt; or = 18; for the samples collected under the NIH grant, no subjects below the&#xD;
             age of 20 will be enrolled.&#xD;
&#xD;
          2. Prior diagnosis of cancer or suspected of having cancer&#xD;
&#xD;
          3. Karnofsky performance status of greater than 70&#xD;
&#xD;
          4. Standard pretreatment evaluation&#xD;
&#xD;
          5. Signed Stanford University Human Subjects Committee consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maximilian Diehn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rene Bonilla</last_name>
    <phone>650-498-7703</phone>
    <email>rbonilla@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rene Bonilla</last_name>
      <phone>650-498-7703</phone>
      <email>rbonilla@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Maximilian Diehn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 5, 2006</study_first_submitted>
  <study_first_submitted_qc>July 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2006</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

